Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Is the Biotech IPO Window Closing?

This article was originally published in Scrip

Executive Summary

Drug developers are filing for initial public offerings at a brisk pace in October despite falling biotechnology stock values and the struggle to price first-time offerings attractively, which begs the question: Are biotech companies afraid that the IPO window is about to close?

Advertisement

Related Content

Wave Keeps Neuro Focus Via Pfizer Collaboration For Five Metabolic Targets
AbbVie Partnership On CD71 Gives CytomX Big Upfront, Co-Promotion Potential

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register